Preclinical activity of REGN-M114 showed activity in EGFR mutant NSCLC with PTEN loss or MET Y1230C mutation cell lines that were pretreated with osimertinib and savolitinib (37). This evidence concerns the gene EGFR and non-small cell lung carcinoma.